Fig. 2

Prevalence of PD-L1 expression in soft-tissue sarcomas across published studies. This figure shows the levels of PD-L1 expression in different sarcoma subtypes that has been reported across a number of studies [79, 81,82,83,84,85,86,87,88,89,90]. Inter- and intra-variability of PD-L1 expression among different sarcoma subtypes warrants extensive studies to establish the use of existing PD-L1 assays as a reliable predictive biomarker to immune checkpoint inhibition in soft tissue sarcomas (STS). ARMS: Alveolar rhabdomyosarcoma; ASPS: Alveolar soft part sarcoma; DDLPS: Dedifferentiated liposarcoma; ERMS: Embryonal rhabdomyosarcoma; ES: Ewing sarcoma; LMS: Leiomyosarcoma; LPS: Liposarcoma; MFS: Myxofibrosarcoma; MPNST: Malignant peripheral nerve sheath tumor; OGS: Osteosarcoma; PRMS: Pleomorphic rhabdomyosarcoma; SS: Synovial sarcoma; UPS: Undifferentiated pleomorphic sarcoma; WD-LPS: Well differentiated liposarcoma